Higgs Boson Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-06-2024
- Paid Up Capital ₹ 0.48 M
as on 24-06-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
as on 24-06-2024
- Revenue 0.82%
(FY 2022)
- Profit 200.28%
(FY 2022)
- Ebitda 29.53%
(FY 2022)
- Net Worth 4.56%
(FY 2022)
- Total Assets 3.96%
(FY 2022)
About Higgs Boson Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.48 M.
The company currently has active open charges totaling ₹3.00 M.
Gorla Lakshmi, Chandrasekharan Ramesh, Parakunnath Mohankumar, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24233KL2012PTC030755
- Company No.
030755
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 2012
- Date of AGM
16 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Higgs Boson Pharmaceuticals Private Limited offer?
Higgs Boson Pharmaceuticals Private Limited offers a wide range of products and services, including Pharmaceutical Medicine, Proprietary Medicines, Mineral Supplement, Calcium Supplements.
Who are the key members and board of directors at Higgs Boson Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gorla Lakshmi  | Director | 05-Mar-2013 | Current |
| Chandrasekharan Ramesh | Director | 19-May-2012 | Current |
| Parakunnath Mohankumar | Director | 14-Mar-2012 | Current |
| Adangazhipurath Vijayaraghavan | Director | 07-Aug-2012 | Current |
| Juby Joseph | Director | 07-Aug-2012 | Current |
| Tharayil Jayachandran | Director | 14-Mar-2012 | Current |
Financial Performance of Higgs Boson Pharmaceuticals.
Higgs Boson Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.82% increase. The company also saw a substantial improvement in profitability, with a 200.28% increase in profit. The company's net worth moved up by a moderate rise of 4.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Higgs Boson Pharmaceuticals?
In 2017, Higgs Boson Pharmaceuticals had a promoter holding of 54.21% and a public holding of 45.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 17 Feb 2023 | ₹3.00 M | Open |
How Many Employees Work at Higgs Boson Pharmaceuticals?
Unlock and access historical data on people associated with Higgs Boson Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Higgs Boson Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Higgs Boson Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
